{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:10:19Z","timestamp":1788905419100,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner Foundation","doi-asserted-by":"publisher","award":["YTCR 08\/20"],"award-info":[{"award-number":["YTCR 08\/20"]}],"id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaut.2026.103608","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:12:50Z","timestamp":1786090370000},"page":"103608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A systematic review of abatacept and belatacept in immune-mediated diseases"],"prefix":"10.1016","volume":"163","author":[{"given":"Alissa M.","family":"Krek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-0246","authenticated-orcid":false,"given":"Miro E.","family":"Raeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2026.103608_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncprheum0345","article-title":"Drug insight: abatacept for the treatment of rheumatoid arthritis","volume":"2","author":"Ruderman","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MOT.0000000000001033","article-title":"Use of belatacept in kidney transplantation: what's new?","volume":"28","author":"Yakubu","year":"2023","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","article-title":"Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis","volume":"65","author":"Nurmohamed","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5152\/eurjrheum.2021.21027","article-title":"How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: a real world study","volume":"9","author":"Jawad","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103608_bib11","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.jaut.2026.103608_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jaut.2026.103608_bib15","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-018-1769-7","article-title":"Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-017-1364-3","article-title":"Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis","volume":"19","author":"Szentpetery","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.jaut.2026.103608_bib18","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"13","key":"10.1016\/j.jaut.2026.103608_bib19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1177\/0961203316640911","article-title":"Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease","volume":"25","author":"Danion","year":"2016","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2014.10.038","article-title":"Treatment of coexistent psoriasis and lupus erythematosus","volume":"72","author":"Varada","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"10.1016\/j.jaut.2026.103608_bib21","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept","volume":"66","author":"Askanase","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis A twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000355","article-title":"Belatacept in kidney transplant patients with systemic lupus erythematosus","volume":"6","author":"Carri\u00f3n-Barber\u00e0","year":"2019","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2026.103608_bib24","article-title":"Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus","volume":"2023","author":"Ikeda","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib25","doi-asserted-by":"crossref","first-page":"E699","DOI":"10.1097\/RHU.0000000000001837","article-title":"Potential benefit of rituximab in rhupus patients from a single-center: a series of 16 cases","volume":"28","author":"Rottenberg","year":"2022","journal-title":"Jcr-J. Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib26","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary sjogren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2026.103608_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary sjogren's syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib28","first-page":"2362","article-title":"Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sj\u00f6gren's disease patients","volume":"42","author":"Nakshbandi","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2026.103608_bib30","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary sjogren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"7","key":"10.1016\/j.jaut.2026.103608_bib31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib32","first-page":"317","article-title":"Abatacept treatment of patients with primary sjogren's syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary sjogren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3899\/jrheum.160459","article-title":"Detailed analysis of the articular domain in patients with primary Sjogren syndrome","volume":"44","author":"Moerman","year":"2017","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","article-title":"Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial","volume":"26","author":"Tsuboi","year":"2016","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/mr\/roac011","volume":"33","author":"Tsuboi","year":"2023","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/14397595.2017.1349234","article-title":"Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sjogren's syndrome associated with rheumatoid arthritis: utility to evaluate and predict response to treatment","volume":"28","author":"Takahashi","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib40","doi-asserted-by":"crossref","first-page":"E743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib41","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience","volume":"50","author":"Castellvi","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009742.2013.812238","article-title":"Abatacept induces clinical improvement in patients with severe systemic sclerosis","volume":"43","author":"de Paoli","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103608_bib43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib44","doi-asserted-by":"crossref","first-page":"NP5","DOI":"10.1177\/2397198318766819","article-title":"Abatacept to treat chronic intestinal pseudo-obstruction in five systemic sclerosis patients with a description of the index case","volume":"4","author":"Vigone","year":"2019","journal-title":"J. Scleroderma Relat. Disord."},{"key":"10.1016\/j.jaut.2026.103608_bib45","series-title":"Clinical and Experimental Rheumatology","article-title":"Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases","author":"Lebel","year":"2024"},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Wehner","year":"2018","journal-title":"Acta Derm. Venereol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib48","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2026.103608_bib50","article-title":"Efficacy and safety of subcutaneous abatacept + standard treatment for active idiopathic inflammatory myopathy: phase III randomised controlled trial","author":"Aggarwal","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2026.103608_bib52","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib53","first-page":"377","article-title":"Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series","volume":"42","author":"Xia","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9388","key":"10.1016\/j.jaut.2026.103608_bib54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib55","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1016\/S2665-9913(21)00359-3","article-title":"Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study","volume":"4","author":"Matza","year":"2022","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib56","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS) : a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib57","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00259-023-06557-x","article-title":"18F FDG PET\/CT for therapeutic assessment of abatacept in early-onset polymyalgia rheumatica","volume":"51","author":"Allard","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib58","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3899\/jrheum.210455","article-title":"Abatacept as adjunctive therapy in refractory polymyalgia rheumatica","volume":"48","author":"Toussirot","year":"2021","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib59","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.55563\/clinexprheumatol\/l0hd9v","article-title":"An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis","volume":"39","author":"Rossi","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib61","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of takayasu arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103608_bib62","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2026.103608_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejim.2021.10.028","article-title":"Off-label use of biologics for the treatment of refractory and\/or relapsing granulomatosis with polyangiitis","volume":"96","author":"Mettler","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"11","key":"10.1016\/j.jaut.2026.103608_bib64","first-page":"2167","article-title":"Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response","volume":"42","author":"Leffers","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2026.103608_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241275822","article-title":"Uveitis in paediatric Beh\u00e7et disease: a large multicentric Italian cohort","volume":"16","author":"Maccora","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib66","doi-asserted-by":"crossref","first-page":"rkx004","DOI":"10.1093\/rap\/rkx004","article-title":"Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Behcet's disease","volume":"1","author":"Maciel","year":"2017","journal-title":"Rheumatol. Adv. Pract."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib67","first-page":"265","article-title":"Efficacy of abatacept in a refractory case of adult-onset still's disease","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","article-title":"Refractory adult-onset still disease successfully treated with abatacept","volume":"17","author":"Ostrowski","year":"2011","journal-title":"Jcr-J. Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib69","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/annrheumdis-2013-203319","article-title":"Abatacept in relapsing polychondritis","volume":"72","author":"Peng","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib70","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/annrheumdis-2017-212705","article-title":"Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study","volume":"77","author":"Moulis","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib71","first-page":"937","article-title":"Biologics in relapsing polychondritis: a case series","volume":"31","author":"Moulis","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbspin.2011.02.018","article-title":"Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition","volume":"79","author":"Lekpa","year":"2012","journal-title":"Jt. Bone Spine"},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib73","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2026.103608_bib74","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis the PAUSE randomized clinical trial","volume":"157","author":"Harris","year":"2021","journal-title":"Jama Dermatol."},{"issue":"9","key":"10.1016\/j.jaut.2026.103608_bib75","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib76","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2020.09.091","article-title":"An open-label study evaluating the efficacy of abatacept in alopecia areata","volume":"84","author":"Mackay-Wiggan","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2026.103608_bib78","article-title":"Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis","volume":"140","author":"Beretta-Piccoli","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2026.103608_bib79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.jaut.2026.103608_bib80","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/01.wnl.0000325915.00112.61","article-title":"CTLA4Ig treatment in patients with multiple sclerosis - an open-label, phase 1 clinical trial","volume":"71","author":"Viglietta","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib81","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/1352458516662727","article-title":"ACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis","volume":"23","author":"Khoury","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jaut.2026.103608_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1415106","article-title":"A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis","volume":"15","author":"Thonhoff","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jaut.2026.103608_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/bjo-2022-321585","article-title":"Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial","volume":"108","author":"Schauwvlieghe","year":"2024","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2026.103608_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.851453","article-title":"Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience","volume":"10","author":"Maccora","year":"2022","journal-title":"Front. Pediatr."},{"issue":"10","key":"10.1016\/j.jaut.2026.103608_bib86","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00417-015-3140-x","article-title":"Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series","volume":"253","author":"Marrani","year":"2015","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib87","doi-asserted-by":"crossref","first-page":"NP118","DOI":"10.1177\/1120672120981874","article-title":"Long term follow-up and effect of immunosuppression in acute zonal occult outer retinopathy","volume":"32","author":"Guijarro","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"issue":"25","key":"10.1016\/j.jaut.2026.103608_bib88","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-Positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00467-022-05549-7","article-title":"Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal","volume":"38","author":"Burke","year":"2023","journal-title":"Pediatr. Nephrol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib90","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1681\/ASN.2015091002","article-title":"B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS","volume":"27","author":"Delville","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00467-014-2957-6","article-title":"Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis","volume":"30","author":"Garin","year":"2015","journal-title":"Pediatr. Nephrol."},{"issue":"9","key":"10.1016\/j.jaut.2026.103608_bib92","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/tri.12574","article-title":"Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"28","author":"Grellier","year":"2015","journal-title":"Transpl. Int."},{"key":"10.1016\/j.jaut.2026.103608_bib93","doi-asserted-by":"crossref","first-page":"178","DOI":"10.6002\/ect.MESOT2018.P53","article-title":"Successful treatment with abatacept in recurrent focal segmental glomerulosclerosis after kidney transplant","volume":"17","author":"Shah","year":"2019","journal-title":"Exp. Clin. Transplant."},{"issue":"9789","key":"10.1016\/j.jaut.2026.103608_bib94","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaut.2026.103608_bib95","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-Up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib96","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib97","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.201207-1205OC","article-title":"A randomized controlled trial to evaluate inhibition of T-Cell costimulation in allergen-induced airway inflammation","volume":"187","author":"Parulekar","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.jaut.2026.103608_bib98","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2019.11.010","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","volume":"50","author":"Kang","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.jaut.2026.103608_bib99","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.jaip.2019.06.011","article-title":"Abatacept as a long-term targeted therapy for LRBA deficiency","volume":"7","author":"Kiykim","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology-in Practice."},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib101","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib102","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2021013496","article-title":"Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects","volume":"139","author":"Dhunputh","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaut.2026.103608_bib103","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.gendis.2020.03.001","article-title":"Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency","volume":"8","author":"Yang","year":"2021","journal-title":"Genes Dis."},{"issue":"15","key":"10.1016\/j.jaut.2026.103608_bib104","doi-asserted-by":"crossref","first-page":"E1560","DOI":"10.1212\/WNL.0000000000207609","article-title":"Clinical, radiologic, and immunologic features of patients with CTLA4 deficiency with neurologic involvement","volume":"101","author":"Coustal","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jaut.2026.103608_bib105","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib106","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2026.103608_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.704261","article-title":"Rituximab and abatacept are effective in differential treatment of interstitial lymphocytic lung disease in children with primary immunodeficiencies","volume":"12","author":"Rodina","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103608_bib108","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaip.2020.10.028","article-title":"Abatacept use is associated with steroid dose reduction and improvement in fatigue and CD4-Dysregulation in CVID patients with interstitial lung disease","volume":"9","author":"von Spee-Mayer","year":"2021","journal-title":"J. Allergy Clin. Immunol.: Pract."},{"issue":"9","key":"10.1016\/j.jaut.2026.103608_bib109","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/trf.14907","article-title":"Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept","volume":"58","author":"Hess","year":"2018","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.jaut.2026.103608_bib110","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1093\/rheumatology\/keac054","article-title":"VEXAS syndrome: favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up","volume":"61","author":"Pathmanathan","year":"2022","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.jaut.2026.103608_bib111","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jaut.2026.103608_bib112","author":"Myers Squibb"},{"key":"10.1016\/j.jaut.2026.103608_bib113","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","volume":"119","author":"Atienza-Mateo","year":"2024","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103608_bib114","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","article-title":"Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients","volume":"61","author":"Fern\u00e1ndez-D\u00edaz","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2026.103608_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152517","article-title":"Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients","volume":"68","author":"L\u00f3pez-Maraver","year":"2024","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:55:07Z","timestamp":1788904507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":111,"alternative-id":["S0896841126000867"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103608","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of abatacept and belatacept in immune-mediated diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103608"}}